PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
 
Infect Immun. 1978 September; 21(3): 925–930.
PMCID: PMC422085

Interferon treatment of NZB mice: accelerated progression of autoimmune disease.

Abstract

The effect of long-term administration of interferon in New Zealand Black and New Zealand Black/New Zealand White F1 hybrid mice was studied. Treatment with moderate doses of interferon (10(4) units, five times weekly for 8 weeks) did not depress murine leukemia virus gp69/71 levels in serum and spleen, nor p30 levels in the spleen. Interferon given at 10(5.1) units (three times weekly for 37 weeks) caused an increased incidence of anti-erythrocyte antibodies in New Zealand Black mice. Finally, the hybrid mice given interferon at 10(6.0) units (three times weekly for 33 weeks) had increased renal immune complex deposits and increased incidences of proteinuria and anemia.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aarden LA, de Groot ER, Feltkamp TE. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci. 1975 Jun 30;254:505–515. [PubMed]
  • Billiau A, Sobis H, De Somer P. Influence of interferon on virus particle formation in different oncornavirus carrier cell lines. Int J Cancer. 1973 Nov 15;12(3):646–653. [PubMed]
  • Carpenter DF, Steinberg AD, Schur PH, Talal N. The pathogenesis of autoimmunity in New Zealand mice. II. Acceleration of glomerulonephritis by polyinosinic-polycytidylic acid. Lab Invest. 1970 Dec;23(6):628–634. [PubMed]
  • De Somer P, Edy VG, Billiau A. Interferon-induced skin reactivity in man. Lancet. 1977 Jul 2;2(8027):47–48. [PubMed]
  • Friedman RM, Chang EH, Ramseur JM, Myers MW. Interferon-directed inhibition of chronic murine leukemia virus production in cell cultures: lack of effect on intracellular viral markers. J Virol. 1975 Sep;16(3):569–574. [PMC free article] [PubMed]
  • Gresser I, Maury C, Tovey M, Morel-Maroger L, Pontillon F. Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature. 1976 Sep 30;263(5576):420–422. [PubMed]
  • Lambert PH, Dixon FJ. Pathogenesis of the glomerulonephritis of NZB/W mice. J Exp Med. 1968 Mar 1;127(3):507–522. [PMC free article] [PubMed]
  • Levy JA, Kazan P, Varnier O, Kleiman H. Murine xenotropic type C viruses I. Distribution and further characterization of the virus in NZB mice. J Virol. 1975 Oct;16(4):844–853. [PMC free article] [PubMed]
  • Melief CJ, Louie S, Schwartz RS. Ecotropic leukemia viruses in congenic C57BL mice: natural dissemination by milk-borne infection. J Natl Cancer Inst. 1975 Sep;55(3):691–698. [PubMed]
  • Mellors RC, Aoki T, Huebner RJ. Further implication of murine leukemia-like virs in the disorders of NZB mice. J Exp Med. 1969 May 1;129(5):1045–1062. [PMC free article] [PubMed]
  • Mellors RC, Shirai T, Aoki T, Huebner RJ, Krawczynski K. Wild-type Gross leukemia virus and the pathogenesis of the glomerulonephritis of New Zealand mice. J Exp Med. 1971 Jan 1;133(1):113–132. [PMC free article] [PubMed]
  • Oldstone MB. Virus neutralization and virus-induced immune complex disease. Virus-antibody union resulting in immunoprotection or immunologic injury--two sides of the same coin. Prog Med Virol. 1975;19:84–119. [PubMed]
  • Rivière Y, Gresser I, Guillon JC, Tovey MG. Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice. Proc Natl Acad Sci U S A. 1977 May;74(5):2135–2139. [PubMed]
  • Rovenský J, Doskocil J, Pekárek J, Borecký L, Zitnan D, Svejcar J. Prevention of spontaneous autoimmunity to DNA in NZB/Swiss mice by treatment with natural double-stranded RNA. Immunology. 1975 Oct;29(4):745–748. [PubMed]
  • Shapiro SZ, Strand M, Billiau A. Synthesis and cleavage processing of oncornavirus proteins during interferon inhibition of virus particle release. Infect Immun. 1977 Jun;16(3):742–747. [PMC free article] [PubMed]
  • Steinberg AD, Baron S, Talal N. The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A. 1969 Aug;63(4):1102–1107. [PubMed]
  • Strand M, August JT. Oncornavirus envelope glycoprotein in serum of mice. Virology. 1976 Nov;75(1):130–144. [PubMed]
  • Talal N, Steinberg AD. The pathogenesis of autoimmunity in New Zealand black mice. Curr Top Microbiol Immunol. 1974;64(0):79–103. [PubMed]
  • Walker SE. Accelerated mortality in young NZB/NZW mice treated with the interferon inducer tilorone hydrochloride. Clin Immunol Immunopathol. 1977 Sep;8(2):204–212. [PubMed]
  • Yoshiki T, Mellors RC, Strand M, August JT. The viral envelope glycoprotein of murine leukemia virus and the pathogenesis of immune complex glomerulonephritis of New Zealand mice. J Exp Med. 1974 Oct 1;140(4):1011–1027. [PMC free article] [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)